Chemotherapy against human African trypanosomiasis: Is there a road to success?
- 20 October 2010
- journal article
- review article
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 137 (14) , 1987-1994
Abstract
SUMMARY: For over fifty years, human African trypanosomiasis (HAT, sleeping sickness) has been treated with suramin, pentamidine and the very toxic organo-arsenical melarsoprol that was the only drug available for effective treatment of the second stage of the disease. Recently there have been significant efforts using molecular and biochemical approaches to drug design, including high-throughput screening, but the number of lead compounds with promising activity againstT. bruceispp. and an acceptable toxicity index has remained astonishingly small. Clinical research continues to be difficult due to the economic constraints and the complexity of trials on a low prevalence disease in remote and impoverished African regions. Despite those limitations the situation for the patients is improving thanks to the combination of a number of critical factors. By the late 1990s the disease had reached epidemic levels that triggered political support. WHO would sign a donation agreement with the manufacturers for all drugs to treat HAT. A result of this agreement was that eflornithine which is much safer than melarsoprol became available and widely used by non-governmental organizations. TheImpamelI and II programmes demonstrated that against all odds the conduct of clinical trials on HAT was feasible. This allowed the initiation of trials on combination therapies which eventually resulted in the nifurtimox-eflornithine combination treatment (NECT). This combination is currently being introduced as first line treatment, and there is even the prospect of having a new compound, fexinidazole, in the development pipeline. This review summarizes the key information about the existing drugs and gives a comprehensive summary about the recent and currently ongoing efforts towards new drugs.Keywords
This publication has 28 references indexed in Scilit:
- Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialThe Lancet, 2009
- Enantioselective and Nonlinear Intestinal Absorption of Eflornithine in the RatAntimicrobial Agents and Chemotherapy, 2008
- Pentamidine Dosage: A Base/Salt ConfusionPLOS Neglected Tropical Diseases, 2008
- Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort studyBMJ, 2008
- Human African trypanosomiasis: pharmacological re‐engagement with a neglected diseaseBritish Journal of Pharmacology, 2007
- Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case SeriesPLOS Neglected Tropical Diseases, 2007
- Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in UgandaPLoS Clinical Trials, 2006
- High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central ZaireTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'IvoireTransactions of the Royal Society of Tropical Medicine and Hygiene, 1991
- Handbook of Drugs for Tropical Parasitic InfectionsJournal of Parasitology, 1988